Literature DB >> 12720126

14q32 Translocations discriminate IgM multiple myeloma from Waldenstrom's macroglobulinemia.

Hervé Avet-Loiseau1, Richard Garand, Laurence Lodé, Nelly Robillard, Régis Bataille.   

Abstract

Even though the diagnosis of Waldenstrom's macroglobulinemia WM is usually clear, the differential diagnosis with IgM multiple myeloma (MM) might be possible. IgM MM is usually characterized by the accumulation of small mature plasma cells within the bone marrow, and the detection of a monoclonal IgM in the serum. However, in contrast with classical MM, IgM MM is rarely associated with these patients' extensive osteolytic lesions. We analyzed eight cases of IgM MM. None presented with extensive bone lesions. All cases were characterized by the presence of small mature plasma cells within the bone marrow. Molecular cytogenetic analysis revealed a t(11;14) in seven of the eight cases. In contrast, a similar analysis in 17 WM cases failed to detect any t(11;14) cases. We performed further fluorescence in situ hybridization (FISH) experiments, focused on the 14q32 region, and especially on the IgH gene. In contrast to MM (in which illegitimate IgH rearrangements are common), we did not detect any abnormality in the WM cases. In conclusion, even though the cells of origin in WM and MM are mature heavily mutated cells, they differ by the IgH gene rearrangements. Especially in IgM MM, the search for t(11;14) might be useful in difficult cases to discriminate with WM. Copyright 2003 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12720126     DOI: 10.1053/sonc.2003.50053

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  8 in total

1.  IgM multiple myeloma: disease definition, prognosis, and differentiation from Waldenstrom's macroglobulinemia.

Authors:  Steven R Schuster; Sundararajan Vincent Rajkumar; Angela Dispenzieri; William Morice; Alvaro Moreno Aspitia; Stephen Ansell; Robert Kyle; Joseph Mikhael
Journal:  Am J Hematol       Date:  2010-11       Impact factor: 10.047

Review 2.  Update on therapeutic options in Waldenström macroglobulinemia.

Authors:  Xavier Leleu; Julie Gay; Aldo M Roccaro; Anne-Sophie Moreau; Stephanie Poulain; Remy Dulery; Berenice Bro Des Champs; Daniela Robu; Irene M Ghobrial
Journal:  Eur J Haematol       Date:  2009-01       Impact factor: 2.997

3.  Waldenstrom macroglobulinemia.

Authors:  Xavier Leleu; Aldo M Roccaro; Anne-Sophie Moreau; Sophie Dupire; Daniela Robu; Julie Gay; Evdoxia Hatjiharissi; Nicholas Burwik; Irene M Ghobrial
Journal:  Cancer Lett       Date:  2008-06-13       Impact factor: 8.679

4.  Management of lytic bone disease in lymphoplasmacytic lymphoma: A case report and review of the literature.

Authors:  Mizba Baksh; Liuyan Jiang; Unnati Bhatia; Victoria Alegria; Taimur Sher; Vivek Roy; Asher Chanan-Khan; Sikander Ailawadhi; Ricardo D Parrondo
Journal:  Clin Case Rep       Date:  2021-12-07

Review 5.  How to manage Waldenstrom's macroglobulinemia.

Authors:  C Buske; V Leblond
Journal:  Leukemia       Date:  2013-02-06       Impact factor: 11.528

6.  Comprehensive genomic profiling of IgM multiple myeloma identifies IRF4 as a prognostic marker.

Authors:  Daeun Ryu; Hee Jin Kim; Je-Gun Joung; Hae-Ock Lee; Joon Seol Bae; Seok Jin Kim; Haesu Kim; Woong-Yang Park; Kihyun Kim
Journal:  Oncotarget       Date:  2016-07-26

Review 7.  Current applications of multiparameter flow cytometry in plasma cell disorders.

Authors:  T Jelinek; R Bezdekova; M Zatopkova; L Burgos; M Simicek; T Sevcikova; B Paiva; R Hajek
Journal:  Blood Cancer J       Date:  2017-10-20       Impact factor: 11.037

8.  Clinical Presentation and Gene Expression Profiling of Immunoglobulin M Multiple Myeloma Compared With Other Myeloma Subtypes and Waldenström Macroglobulinemia.

Authors:  Shebli Atrash; Qing Zhang; Xenofon Papanikolaou; Caleb Stein; Al-Ola Abdallah; Bart Barlogie
Journal:  J Glob Oncol       Date:  2017-05-09
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.